摘要
目的:探讨替格瑞洛致不良反应(ADR)的一般规律和特点,为临床合理用药提供参考。方法:随访我院2013年12月-2015年6月间使用替格瑞洛的患者672例,对其服药后的ADR情况进行分析、总结。结果:参与调查的672例患者共有78例(11.6%)发生了108例次ADR,男女比例为5.5∶1,差异有统计学意义(P〈0.05);51~60岁患者最多(37.2%);主要累及器官/系统为呼吸系统(41.7%)和皮肤及其附件(38.0%),主要临床表现为轻微出血(78.7%)、呼吸困难(17.6%)和心跳减慢(2.8%)等;未发现严重的ADR。结论:替格瑞洛具有良好的安全性和耐受性,但由于其上市时间较短,且在亚洲人群中缺少大规模的临床试验的循证医学证据,临床应加强用药监测,减少ADR发生,确保用药安全。
OBJECTIVE: To explore the general regulation and characteristics of adverse drug reactions (ADR) induced by ticagrelor, and provide reference for clinical rational drug use. METHODS: 672 patients received ticagrelor in our hospital from Dec. 2013 to Jun. 2015 were followed-up, and the situation was analyzed and summarized after taking drug. RESULTS: In the 672 patients, 78 (11.6%) patients suffered from 108 cases of ADR, the ratio of male to female was 5.5:1, there was statistical significance (P〈0.05) ; patients mostly aged 51-60 years (37.2%) ; the mainly involved organs/systems were respiratory system (41.7%) , and skin and its appendages (38.0%) , the main clinical manifestations were minor bleeding (78.7%) , dyspnea (17.6%) and bradycardia (2.8%) ;no severe ADR was found. CONCLUSIONS: Ticagrelor had good safety and tolerability, but due to its shorter time to market in China and absense of evidence-based medicine for large-scale clinical trials in Asian population, clinic should strengthen medication monitoring to reduce the ADR and ensure drug safety.
出处
《中国药房》
CAS
北大核心
2016年第29期4085-4087,共3页
China Pharmacy
关键词
替格瑞洛
不良反应
监测
分析
Ticagrelor
Adverse drug reaction
Monitoring
Analysis